Pharmaceutical Research

, 36:141 | Cite as

Changes of Blood-Brain Barrier and Brain Parenchymal Protein Expression Levels of Mice under Different Insulin-Resistance Conditions Induced by High-Fat Diet

  • Seiryo Ogata
  • Shingo Ito
  • Takeshi Masuda
  • Sumio OhtsukiEmail author
Research Paper



The purpose of the present study was to investigate changes of blood-brain barrier (BBB) and brain parenchymal protein expression due to type II diabetes mellitus (T2DM) induced by a high-fat diet (HFD) by using SWATH-based quantitative proteomics.


Mice were fed a HFD for 2 or 10 weeks, and then SWATH-based quantitative proteomic analysis, western blot analysis, immunohistochemistry and functional transport studies were performed.


In brain capillaries, expression levels of BBB transporters (Glut1, P-glycoprotein) and tight-junction proteins (claudin-5, occludin) were significantly reduced in HFD mice at 2 weeks, but recovered to the levels in the normal diet (ND) group at 10 weeks. P-glycoprotein function at the BBB was reduced at 2 weeks. In the cerebral cortex and hippocampus, neurofilament, which is important for neuronal function, was decreased in HFD mice at 2 weeks, but recovered at 10 weeks.


Our results suggest that changes in the status of insulin resistance influence expression of BBB transporters, which in turn may alter the expression of cognitive function-related proteins.

Key Words

Blood-brain barrier central nervous system insulin resistance quantitative proteomics type II diabetes mellitus 


Amyloid β peptide


Alzheimer’s disease


Blood-brain barrier


Ca2+/calmodulin-dependent protein kinase


Central nervous system


Glyceraldehyde-3-phosphate dehydrogenase


Glucose transporter 1


human cerebral vascular endothelial cell


High-fat diet


Information-dependent acquisition


Large neutral amino acids transporter small subunit 1


Low density lipoprotein receptor-related protein 1


Monocarboxylate transporter 1


Multidrug resistance protein 1a


Normal diet


Phosphate buffered saline


Post synaptic density


Phase-transfer surfactant


Reactive oxygen species


Sequential window acquisition of all theoretical fragment-ion spectra


Type 2 diabetes mellitus


Tricarboxylic acid


Transferrin receptor


Tumor necrosis factor-alpha


Vascular endothelial growth factor


Acknowledgments and Disclosures

We are grateful for partial financial support in the form of three Grants-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science (JSPS) and a Grant-in-Aid for Scientific Research on Innovative Areas (15H01562), as well as a grant from the Mochida Memorial Foundation for Medical and Pharmaceutical Research. Ohtsuki S is a full professor at Kumamoto University and is also a director of Proteomedix Frontiers. This study was not supported by the company, and his position at the company did not influence the design of the study, the collection of the data, the analysis or interpretation of the data, the decision to submit the manuscript for publication, or the writing of the manuscript, and did not present any financial conflicts. The other authors declare no competing interests.

Author Contributions

All authors, Ogata S, Ito S, Masuda T and Ohtsuki S, contributed to study design and manuscript revision. Ogata S conducted experiments and performed data analysis. Ogata S, Ito S. and Ohtsuki S wrote the manuscript. All authors provided final approval of the submitted manuscript.

Supplementary material

11095_2019_2674_MOESM1_ESM.docx (1.2 mb)
ESM 1 (DOCX 1.18 mb)
11095_2019_2674_MOESM2_ESM.xlsx (275 kb)
Table S4 Identified proteins in brain capillary fraction of mice fed with HFD for 2 weeks (A) or 10 weeks (B) by SWATH-MS. (XLSX 275 kb)
11095_2019_2674_MOESM3_ESM.xlsx (980 kb)
Table S5 Identified proteins in cerebral cortex cytosol (A, C) or plasma membrane (B, D) fraction of mice fed with HFD for 2 weeks (A, B) or 10 weeks (C, D) by SWATH-MS. (XLSX 980 kb)
11095_2019_2674_MOESM4_ESM.xlsx (937 kb)
Table S6 Identified proteins in hippocampus cytosol (A, C) or plasma membrane (B, D) fraction of mice fed with HFD for 2 weeks (A, B) or 10 weeks (C, D) by SWATH-MS. (XLSX 936 kb)


  1. 1.
    Marin-Valencia I, Good LB, Ma Q, Duarte J, Bottiglieri T, Sinton CM, et al. Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype. Neurobiol Dis. 2012;48(1):92–101.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015;18(4):521–30.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Liu L, Liu XD. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 2014;5:273.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115(11):3285–90.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012;9(1):23.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Hamed SA. Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications. Expert Rev Clin Pharmacol. 2017;10(4):409–28.PubMedCrossRefGoogle Scholar
  7. 7.
    Yang W, Shi H, Zhang J, Shen Z, Zhou G, Hu M. Effects of the duration of hyperlipidemia on cerebral lipids, vessels and neurons in rats. Lipids Health Dis. 2017;16(1):26.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007;50(1):202–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Ouyang S, Hsuchou H, Kastin AJ, Wang Y, Yu C, Pan W. Diet-induced obesity suppresses expression of many proteins at the blood-brain barrier. J Cereb Blood Flow Metab. 2014;34(1):43–51.CrossRefGoogle Scholar
  10. 10.
    Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012;122(1):153–62.CrossRefGoogle Scholar
  11. 11.
    Jais A, Solas M, Backes H, Chaurasia B, Kleinridders A, Theurich S, et al. Myeloid-cell-derived VEGF maintains brain glucose uptake and limits cognitive impairment in obesity. Cell. 2016;165(4):882–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Kanoski SE, Davidson TL. Different patterns of memory impairments accompany short- and longer-term maintenance on a high-energy diet. Journal of experimental psychology. Animal behavior processes. 2010;36(2):313–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Parks BW, Sallam T, Mehrabian M, Psychogios N, Hui ST, Norheim F, et al. Genetic architecture of insulin resistance in the mouse. Cell Metab. 2015;21(2):334–47.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Uchida Y, Tachikawa M, Obuchi W, Hoshi Y, Tomioka Y, Ohtsuki S, et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS. 2013;10(1):21.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Masuda T, Tomita M, Ishihama Y. Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J Proteome Res. 2008;7(2):731–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339(2):579–88.PubMedCrossRefGoogle Scholar
  17. 17.
    Silva AJ, Paylor R, Wehner JM, Tonegawa S. Impaired spatial learning in alpha-calcium-calmodulin kinase II mutant mice. Science (New York, N.Y.) 1992; 257(5067): 206–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Yamaguchi M, Kokai Y, Imai S, Utsumi K, Matsumoto K, Honda H, et al. Investigation of annexin A5 as a biomarker for Alzheimer's disease using neuronal cell culture and mouse model. J Neurosci Res. 2010;88(12):2682–92.PubMedGoogle Scholar
  19. 19.
    Howell MD, Bailey LA, Cozart MA, Gannon BM, Gottschall PE. Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice. Acta neuropathologica communications. 2015;3:54.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Di Domenico F, Owen JB, Sultana R, Sowell RA, Perluigi M, Cini C, et al. The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: implications for disease pathogenesis and progression. J Neurosci Res. 2010;88(16):3566–77.PubMedCrossRefGoogle Scholar
  21. 21.
    Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis. 2008;30(1):107–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Cornford EM, Young D, Paxton JW, Hyman S, Farrell CL, Elliott RB. Blood-brain glucose transfer in the mouse. Neurochem Res. 1993;18(5):591–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Roberts EL. 2.1 The support of energy metabolism in the central nervous system with substrates other than glucose. In: Lajtha A, Gibson GE, Dienel GA (eds). Handbook of Neurochemistry and Molecular Neurobiology: Brain Energetics. Integration of Molecular and Cellular Processes. Springer US: Boston, MA, 2007, pp 137–179.CrossRefGoogle Scholar
  24. 24.
    Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68(3):231–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502.PubMedCrossRefGoogle Scholar
  26. 26.
    Schoenfelder Y, Hiemke C, Schmitt U. Behavioural consequences of p-glycoprotein deficiency in mice, with special focus on stress-related mechanisms. J Neuroendocrinol. 2012;24(5):809–17.PubMedCrossRefGoogle Scholar
  27. 27.
    Greene C, Kealy J, Humphries MM, Gong Y, Hou J, Hudson N, et al. Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. Mol Psychiatry. 2017.Google Scholar
  28. 28.
    Ito S, Yanai M, Yamaguchi S, Couraud PO, Ohtsuki S. Regulation of tight-junction integrity by insulin in an in vitro model of human blood-brain barrier. J Pharm Sci. 2017;106(9):2599–605.PubMedCrossRefGoogle Scholar
  29. 29.
    Liem RK, Messing A. Dysfunctions of neuronal and glial intermediate filaments in disease. J Clin Invest. 2009;119(7):1814–24.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Arnold SE, Lucki I, Brookshire BR, Carlson GC, Browne CA, Kazi H, et al. High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol Dis. 2014;67:79–87.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Pierre K, Parent A, Jayet PY, Halestrap AP, Scherrer U, Pellerin L. Enhanced expression of three monocarboxylate transporter isoforms in the brain of obese mice. J Physiol. 2007;583(Pt 2):469–86.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Min SH, Oh TJ, Baek SI, Lee DH, Kim KM, Moon JH, et al. Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. Diabetes Metab. 2018;44(1):73–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Krishna S, Lin Z, de La Serre CB, Wagner JJ, Harn DH, Pepples LM, et al. Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake. Physiol Behav. 2016;157:196–208.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Liu H, Xu X, Yang Z, Deng Y, Liu X, Xie L. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats. Brain Res. 2006;1123(1):245–52.PubMedCrossRefGoogle Scholar
  35. 35.
    Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun. 2010;11:145–56.PubMedCrossRefGoogle Scholar
  36. 36.
    Spagnuolo MS, Mollica MP, Maresca B, Cavaliere G, Cefaliello C, Trinchese G, et al. High fat diet and inflammation - modulation of Haptoglobin level in rat brain. Front Cell Neurosci. 2015;9:479.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol. 2007;71(3):667–75.PubMedCrossRefGoogle Scholar
  38. 38.
    Jain SS, Paglialunga S, Vigna C, Ludzki A, Herbst EA, Lally JS, et al. High-fat diet-induced mitochondrial biogenesis is regulated by mitochondrial-derived reactive oxygen species activation of CaMKII. Diabetes. 2014;63(6):1907–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Maraldi T, Rugolo M, Fiorentini D, Landi L, Hakim G. Glucose transport activation in human hematopoietic cells M07e is modulated by cytosolic calcium and calmodulin. Cell Calcium. 2006;40(4):373–81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical SciencesKumamoto UniversityKumamotoJapan
  2. 2.Department of Pharmaceutical Microbiology, Faculty of Life SciencesKumamoto UniversityKumamotoJapan
  3. 3.AMED-CRESTJapan Agency for Medical Research and DevelopmentTokyoJapan

Personalised recommendations